Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mosapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | HTR1A | P08908 | 1/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.84 |
| ▸ | HTR2C | P28335 | 1/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | HTR2B | P41595 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.84 |
| ▸ | DRD4 | P21917 | 12/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mosapride SCHEMBL6227414 | 1.00 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL30450705 | 1.00 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL14320968 | 1.00 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL8462520 | 0.99 | DRD3 (0.85) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL258620 | 0.99 | DRD3 (0.85) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL2369236 | 0.92 | DRD3 (0.98) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6229365 | 0.92 | DRD3 (0.91) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL29400580 | 0.91 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6228981 | 0.91 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL16417 | 0.91 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108324697-B | Mosapride citrate-containing capsule and preparation method thereof | 科贝源(北京)生物医药科技有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-108324697-A | A kind of capsule and preparation method thereof containing mosapride citrate | 科贝源(北京)生物医药科技有限公司 | 2018-07-27 | — | — | CN | claimed |
| US-8153161-B2 | Medicament-containing particle and a solid preparation containing the particle | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-10 | — | — | US | claimed |
| WO-2011107903-A1 | HIGHLY PURE MOSAPRIDE CITRATE DIHYDRATE AND PROCESSES FOR ITS PREPARATION | RANBAXY LABORATORIES LIMITED (IN) | 2011-09-09 | — | — | WO | claimed |
| US-20070148230-A1 | Medicament-containing particle and a solid preparation containing the particle | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-06-28 | — | — | US | claimed |
| EP-1695699-A1 | DRUG-CONTAINING GRAINS AND SOLID PREPARATION CONTAINING THE GRAINS | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-08-30 | — | — | EP | claimed |
| WO-2006011159-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING RABEPRAZOLE SODIUM WITH IMPROVED BIOAVAILABILITY | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-02-02 | — | — | WO | claimed |
| WO-2004066913-A2 | SOLID MOSAPRIDE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | WO | claimed |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | disclosed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119246725-A | Method for detecting fluorine impurities in mosapride citrate intermediate | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119246710-A | Method for detecting fluorine impurities in mosapride citrate intermediate | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119241463-A | Mosapride citrate impurity compound and preparation method thereof | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2003106440-A2 | PROCESS FOR THE SYNTHESIS OF A BENZAMIDE DERIVATIVE | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003011256-A1 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF A PROKINETIC AGENT | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-02-13 | — | — | WO | disclosed |
| EP-0814840-B1 | ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING A PROTON PUMP INHIBITOR AND A PROKINETIC AGENT | ASTRAZENECA AB (SE) | 2002-11-20 | — | — | EP | disclosed |
| US-6132771-A | USEFUL IN TREATMENT OF DISORDERS ASSOCIATED WITH GASTRO OESOPHAGEAL REFLUX DISEASES | ASTRAZENECA AB (SE) | 2000-10-17 | — | — | US | disclosed |
| EP-0814840-A1 | ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING A PROTON PUMP INHIBITOR AND A PROKINETIC AGENT | Astra Aktiebolag (SE) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997025065-A1 | ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING A PROTON PUMP INHIBITOR AND A PROKINETIC AGENT | ASTRA AKTIEBOLAG (SE) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | HTR4, IL4, FFAR4 | HTR4 1/4885DRD3 398/4885MEN1 4872/4885 |
| US-20070148230-A1 | Medicament-containing particle and a solid preparation containing the particle | TMEM205, MPDU1, MAST4 | HTR4 1169/4885DRD3 709/4885MEN1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.